Medical Costs Associated With Type 2 Diabetes Complications and Comorbidities

被引:1
作者
Li, Rui [1 ]
Bilik, Dori [2 ]
Brown, Morton B. [3 ]
Zhang, Ping [1 ]
Ettner, Susan L. [4 ]
Ackermann, Ronald T. [5 ]
Crosson, Jesse C. [6 ]
Herman, William H. [2 ]
机构
[1] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[4] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] UMDNJ Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA
关键词
PREVALENCE; MELLITUS;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To estimate the direct medical costs associated with type 2 diabetes, its complications, and its comorbidities among US managed care patients. Study Design: Data were from patient surveys, chart reviews, and health insurance claims for 7109 people with type 2 diabetes from 8 health plans participating in the Translating Research Into Action for Diabetes (TRIAD) study between 1999 and 2002. Methods: A generalized linear regression model was developed to estimate the association of patients' demographic characteristics, tobacco use status, treatments, related complications, and comorbidities with medical costs. Results: The mean annualized direct medical cost was $2465 for a white man with type 2 diabetes who had been diagnosed fewer than 15 years earlier, was treated with oral medication or diet alone, and had no complications or comorbidities. We found annualized medical costs to be 10% to 50% higher for women and for patients whose diabetes had been diagnosed 15 or more years earlier, who used tobacco, who were being treated with insulin, or who had several other complications. Coronary heart disease, congestive heart failure, hemiplegia, and amputation were each associated with 70% to 150% higher costs. Costs were approximately 300% higher for end-stage renal disease treated with dialysis and approximately 500% higher for end-stage renal disease with kidney transplantation. Conclusions: Most medical costs incurred by patients with type 2 diabetes are related to complications and comorbidities. Our cost estimates can help when determining the most cost-effective interventions to prevent complications and comorbidities. Am J Manag Care. 2013;19(5):421-430
引用
收藏
页码:421 / 430
页数:10
相关论文
共 18 条
[1]   The direct medical cost of type 2 diabetes [J].
Brandle, M ;
Zhou, HH ;
Smith, BRK ;
Marriott, D ;
Burke, R ;
Tabaei, BP ;
Brown, MB ;
Herman, WH .
DIABETES CARE, 2003, 26 (08) :2300-2304
[2]   Type 2 diabetes: Incremental medical care costs during the first 8 years after diagnosis [J].
Brown, JB ;
Nichols, GA ;
Glauber, HS ;
Bakst, AW .
DIABETES CARE, 1999, 22 (07) :1116-1124
[3]   A new framework for managing and analyzing multiply imputed data in Stata [J].
Carlin, John B. ;
Galati, John C. ;
Royston, Patrick .
STATA JOURNAL, 2008, 8 (01) :49-67
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]  
Curb JD, 2002, DIABETES CARE, V25, P386
[6]   Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland - A retrospective cohort study of resource use [J].
Donnan, PT ;
Leese, GP ;
Morris, AD .
DIABETES CARE, 2000, 23 (12) :1774-1779
[7]   Direct medical costs for patients with type 2 diabetes in Sweden [J].
Henriksson, F ;
Agardh, CD ;
Berne, C ;
Bolinder, J ;
Lönnqvist, F ;
Stenström, P ;
Östenson, CG ;
Jönsson, B .
JOURNAL OF INTERNAL MEDICINE, 2000, 248 (05) :387-396
[8]  
Kahn R, 2004, DIABETES CARE, V27, P2262
[9]   Ethnic disparities in diabetic complications in an insured population [J].
Karter, AJ ;
Ferrara, A ;
Liu, JY ;
Moffet, HH ;
Ackerson, LM ;
Selby, JV .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2519-2527
[10]   Can comorbidity be measured by questionnaire rather than medical record review? [J].
Katz, JN ;
Chang, LC ;
Sangha, O ;
Fossel, AH ;
Bates, DW .
MEDICAL CARE, 1996, 34 (01) :73-84